C. R. Bard, Inc., headquartered in Murray Hill, New Jersey, USA, was a developer, manufacturer, and marketer of medical technologies in the vascular medicine, urology, oncology, and surgical specialty fields.

[citation needed] In 1948, C. R. Bard's annual sales topped $1 million for the first time, and the company moved its headquarters from New York City to Summit, New Jersey.

Over time, the company introduced a variety of new health care products, and its net sales first exceeded $1 billion in 1994.

[9] The transvaginal mesh is a device that is surgically implanted into the vagina to strengthen pelvic muscles or organs, or to treat incontinence.

By 2010, Bard and other makers of vaginal mesh were being sued by women who alleged that the devices were responsible for their medical pain and injuries.

Their legal cases cited poor design and unsafe materials, and claimed that some patients required "multiple surgeries to remove" the device.

[10] In 2012, the U.S. Food and Drug Administration (FDA) required that Bard and other manufacturers study the rates of organ damage linked to the mesh devices.